EVEN WITH
LIFESTYLE
CHANGES, PATIENTS
CAN STILL FACE
HIDDEN CVD RISKS.1

Expose unseen heart health risk.

EVEN WITH LIFESTYLE CHANGES, PATIENTS CAN STILL FACE HIDDEN CVD RISKS.1

Expose unseen heart health risk.

YOUR PATIENTS’ COMORBIDITIES ARE
CRITICAL PREDICTORS OF EARLY CV DISEASE.2,3

YOUR PATIENTS’
COMORBIDITIES ARE CRITICAL PREDICTORS OF EARLY CV DISEASE.2,3

IDENTIFY

Learn how the Cardiac Continuum can help identify the impact of comorbidities on CV health.4,5

____________________________

CONFIRM

Quantify patient risk by measuring existing plaque with coronary artery calcium (CAC) scoring.6-8

____________________________

MANAGE

Once at-risk patients have been identified, proactive management of their risk can improve CV outcomes.9

LEARN MORE

 

 

HELP REVEAL YOUR PATIENTS’
HEART HEALTH RISK

with heart health educational tools on our website, including the Bayer® Aspirin Heart Health Risk Assessment tool, a patient-facing assessment that can help you have a meaningful discussion with your patients about their cardiovascular (CV) risk factors.

LEARN ABOUT THE RISK ASSESSMENT TOOL

HELP REVEAL
YOUR PATIENTS’
HEART HEALTH RISK

with heart health educational tools on our website, including the Bayer® Aspirin Heart Health Risk Assessment tool, a patient-facing quiz that can help you have a meaningful discussion with your patients about their cardiovascular (CV) risk factors.

LEARN ABOUT THE RISK ASSESSMENT TOOL

SEE YOUR RISKS

 

HEART ATTACK RISK
IS MORE RELEVANT THAN EVER

EVERY YEAR, MORE THAN 800,000 PEOPLE IN THE UNITED STATES HAVE A HEART ATTACK10

x ray of chest and heart

HEART ATTACK AND STROKE RISK CAN INCREASE AFTER COVID—EVEN WITH A MILD CASE11

germs glowing as if they are being viewed through night vision goggles
TAKE A LOOK AT HOW WE’RE HELPING RAISE CV RISK AWARENESS AMONG FANS

HEART HEALTH TOOLS & RESOURCES

References: 1. Faridi K, Lahan S, Budoff M, et al. Serum lipoproteins are associated with coronary atherosclerosis in asymptomatic U.S. adults without traditional risk factors. JACC: Adv. 2024;3(7):1-13. 2. Leon B, Maddox T. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246-1258. 3. Chrysant SG. Stopping the cardiovascular disease continuum: Focus on prevention. World J Cardiol. 2010;2(3):43-49. 4. Dzau V, Antman A, Black H, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes part 1: Pathophysiology and clinical trial evidence (Risk factors through stable coronary artery disease). Am He J. 2026. doi:10.1161/CIRCULATIONAHA.106.655688 5. Mesquita E, Demarchi A, Bitencourt D, et al. Cardiovascular continuum 25 years - the evolution of an etiopathophysiology model. Int J of Cardio Sci. 2016;29(1):56-64. 6. Orringer C, Blaha M, Blankstein R, et al. The national lipid association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J of Clin Lipid. 2021;15:33-60. 7. Ihle-Hansen H, Vigen T, Berge T, et al. Carotid Plaque Score for Stroke and Cardiovascular Risk Prediction in a Middle-Aged Cohort From the General Population. J Am Heart Assoc. 2023;12:e030739. doi:10.1161/JAHA.123.030739 8. Jamthikar A, Guptka D, Cuadrado-Godia E, et al. Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on “Integrated Vascular Age” instead of “Chronological Age”: a multi-ethnic study of Asian Indian, Caucasian, and Japanese cohorts. Cardiovasc Diagn Ther. 2020;10(4):939-954. 9. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol. 2025;9(6):S1-S122. doi:10.1016/j.jaci.2025.09.002 10. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics–2019 update. A report from the American Heart Association.